Kv1.3 inhibitors and their medical applications

Abstract

The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , Y, R 2 and R 7 are as defined herein, and methods for producing such compounds.

1 . A compound of the general formula (III) or a salt, solvate or prodrug thereof, 
       
         
           
           
               
               
           
         
         wherein 
         A 1  is selected from the group consisting of N and C-R 8 ; 
         A 2  is selected from the group consisting of N and C-R 3 ; 
         A 3  is selected from the group consisting of N and C-R 9 ; 
         A 4  and A 5  and A 6  are independently selected from the group consisting of N and C-R 1 ; 
         R 1  is selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl, halogen, (C 1 -C 3 )alkoxy and (C 1 -C 3 )haloalkyl; 
         R 2  is selected from the group consisting of hydrogen, halogen and (C 1 -C 3 )alkyl; 
         R 3  is selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl, NR 4 R 5 , (C 1 -C 3 )alkyl-NR 4 R 5  and cyano; 
         wherein R 4  and R 5  are independently selected from the group consisting of hydrogen, (C 3 -C 5 )cycloalkyl, (C 3 -C 5 )heterocycloalkyl, (C 1 -C 3 )alkyl, or R 4  and R 5  together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally comprising in addition to the aforementioned nitrogen atom a further heteroatom group selected from the group consisting of O and NR 6 , wherein R 6  is selected from the group consisting of hydrogen, methyl, acetyl and formyl; 
         Y is selected from the group consisting of O and S; 
         R 7  is selected from the group consisting of hydrogen, and (C 1 -C 3 )alkyl; 
         R 8  is selected from the group consisting of (C 1 -C 4 )alkyl, (C 3 -C 5 )cycloalkyl, and (C 3 -C 5 )heterocycloalkyl; and 
         R 9  is selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy. 
       
     
     
         2 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein if Y is O, at least one of A 1 , A 2  or A 3  is N. 
     
     
         3 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein A 1  is C-R 8 ; A 2  is C-R 3 ; A 3  is C-R 9 ; and Y is O. 
     
     
         4 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein
 R 1  is selected from the group consisting of hydrogen, methyl, chloro, fluoro, methoxy, ethoxy and trifluoromethyl; 
 R 2  is selected from the group consisting of hydrogen, bromo and methyl; 
 R 3  is selected from the group consisting of hydrogen, methyl, morpholinyl, morpholinomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl and cyano; 
 R 7  is selected from the group consisting of hydrogen and methyl; 
 R 8  is selected from the group consisting of methyl, ethyl and cyclopropyl; and 
 R 9  is selected from the group consisting of hydrogen, methyl and methoxy. 
 
     
     
         5 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein
 A 1  is C—CH 3 ; 
 Y is O; 
 A 2  is selected from the group consisting of N and CH; 
 A 3  is selected from the group consisting of N and C—CH 3 , 
 A 4  and A 5  and A 6  are independently selected from the group consisting of N and C-R 1 ; 
 R 1  is selected from the group consisting of hydrogen, methyl, chloro, fluoro and methoxy; 
 R 2  is selected from the group consisting of hydrogen, methyl and bromo; and 
 R 7  is selected from the group consisting of hydrogen and methyl. 
 
     
     
         6 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein
 A 1  is C—CH 3 ; A 2  is C—H; A 3  is C—CH 3 ; Y is O; 
 A 4  and A 5  and A 6  are independently selected from the group consisting of N and C-R 1 ; 
 R 1  is selected from the group consisting of hydrogen, methyl, chloro, fluoro and methoxy; 
 R 2  is selected from the group consisting of hydrogen, methyl and bromo; and 
 R 7  is selected from the group consisting of hydrogen and methyl. 
 
     
     
         7 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, wherein
 A 4  and A 5  and A 6  are independently selected from the group consisting of N and CH; and 
 R 2  is selected from the group consisting of hydrogen and methyl. 
 
     
     
         8 . A compound according to  claim 1  or a salt, solvate or prodrug thereof, which is selected from the group consisting of
 6-bromo-3,9-dimethyl-5-phenylfuro[3,2-g]quinolin-7(8H)-one, 
 6-bromo-5-(2-fluorophenyl)-3,9-dimethylfuro[3,2-g]quinolin-7(8H)-one, 
 6-bromo-3,9-dimethyl-5-(o-tolyl)furo[3,2-g]quinolin-7(8H)-one, 
 3,9-dimethyl-5-(o-tolyl)furo[3,2-g]quinolin-7(8H)-one, 
 5-(2-fluorophenyl)-3,6,9-trimethylfuro[3,2-g]quinolin-7(8H)-one, 
 3,6,9-trimethyl-5-phenylfuro[3,2-g]quinolin-7(8H)-one, 
 3,8,9-trimethyl-5-phenylfuro[3,2-g]quinolin-7(8H)-one, 
 6-bromo-3,8,9-trimethyl-5-phenylfuro[3,2-g]quinolin-7(8H)-one, 
 3,6,8,9-tetramethyl-5-phenylfuro[3,2-g]quinolin-7(8H)-one, 
 3,6,9-trimethyl-5-phenylisoxazolo[4,5-g]quinolin-7(8H)-one, 
 5-(2-chlorophenyl)-3,6,9-trimethylfuro[3,2-g]quinolin-7(8H)-one, 
 3,6,8-trimethyl-5-phenylfuro[2,3-b][1,8]naphthyridin-7(8H)-one, 
 3,9-dimethyl-5-phenylisoxazolo[4,5-g]quinolin-7(8H)-one, 
 3,6,8,9-tetramethyl-5-phenylisoxazolo[4,5-g]quinolin-7(8H)-one, 
 3,6,9-trimethyl-5-(pyridin-3-yl)furo[3,2-g]quinolin-7(8H)-one, 
 3,6,8,9-tetramethyl-5-(pyridin-3-yl)furo[3,2-g]quinolin-7(8H)-one, 
 3,6,8,9-tetramethyl-5-(pyridin-3-yl)isoxazolo[4,5-g]quinolin-7(8H)-one, 
 3,6,8,9-tetramethyl-5-(o-tolyl)furo[3,2-g]quinolin-7(8H)-one, 
 5-(2-chlorophenyl)-3,6,8,9-tetramethylfuro[3,2-g]quinolin-7(8H)-one, 
 5-(2-fluorophenyl)-3,6,8,9-tetramethylfuro[3,2-g]quinolin-7(8H)-one, and 
 5-(2-methoxypyridin-3-yl)-3,6,8,9-tetramethylfuro[3,2-g]quinolin-7(8H)-one, 
 or a salt, solvate or prodrug thereof. 
 
     
     
         9 . A pharmaceutical composition comprising a compound according to  claim 1  and a pharmaceutically acceptable carrier or diluent. 
     
     
         10 . A method for the treatment of diseases or medical conditions comprising administering to a patient a compound according to  claim 1 . 
     
     
         11 . A method for manufacture of a pharmaceutical composition for treating diseases or medical conditions comprising mixing a compound according to  claim 1  with a pharmaceutically acceptable carrier or diluent. 
     
     
         12 . The method according to  claim 10 , wherein said disease or medical condition is a disease or medical condition wherein the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial. 
     
     
         13 . The method according to  claim 12 , wherein said disease or medical condition is selected from the group consisting of psoriasis, psoriatric arthritis, autoimmune thyroiditis, Hashimoto's disease, Grave's disease, rheumatoid arthritis, vitiligo, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis (Morbus Bechterew), periodontal disease, diabetes type I, multiple sclerosis, systemic lupus erythematosus, anti-glomerular basement membrane glomerulonephritis, rapidly progressive glomerulonephritis, advanced chronic renal failure, chronic kidney disease, renal fibrosis, uveitis, pars planitis, asthma, pemphigus foliaceus, inclusion body myositis, dermatomyositis, scleroderma, Behcet disease, atopic dermatitis, allergic and irritant contact dermatitis, Lichen planus, Sjögren's syndrome, Graft-versus-Host-Reaction, Host-versus-Graft-Reaction, transplant rejection, end-stage renal disease, vascularized composite allotransplantation rejection, alopecia areata, inflammatory bone resorption disease, anti-neutrophil cytoplasmic autoantibody-associated vasculitis, osteoarthritis, diseases associated with intimal hyperplasia, breast cancer, leukemia, human lung adenocarcinoma, cutaneous T-cell lymphoma, chronic lymphocytic leukemia, osteosarcoma, neuroblastoma, ovarian cancer and melanoma, neuroinflammatory disorders, neurodegeneration, HIV-1-associated neurocognitive disorders (HAND), microglia-induced oxidative stress in Alzheimer's disease, obesity, and insulin resistance, restenosis/neointimal hyperplasia, atherosclerosis (arteriosclerotic vascular disease or ASVD), acute coronary syndrome, acute ischemic stroke, hypertension. 
     
     
         14 . A method for producing a compound according to formula III of the present invention, wherein A 1  is C-R 8  and A 2  is selected from the group consisting of CH and N; and
 wherein said method is characterized by the following conversion:   
       
         
           
           
               
               
           
         
         wherein A 3 , A 4 , A 5 , A 6 , R 2 , R 7 , R 8  and Y are as defined above; 
         W is selected from the group consisting of 
       
       
         
           
           
               
               
           
         
         wherein R 8  is as defined above, W 2  is selected from the group consisting of CH 2 , CH—CH 3 , C(CH 3 ) 2 , CH—CH 2 —CH 3 , C(CH 3 )—CH 2 —CH 3 , CH—CH(CH 3 )—CH 3 , and CH—CH 2 —CH 2 —CH 3 , and said method further comprises the step of transition metal mediated intramolecular alkylation at the position marked with an asterisk in the above formula III′; 
         or W is hydrogen and said method further comprises transition metal mediated acylation at the position marked with an asterisk in the above formula III′ using 
       
       
         
           
           
               
               
           
         
         wherein W 2  is as defined above and R c  is (C 1 -C 4 )alkyl; followed by cyclization using hydroxylamine.